CK Life Sciences Int'l., (Holdings) Inc. (FRA:LSI)

Germany flag Germany · Delayed Price · Currency is EUR
0.0780
-0.0010 (-1.27%)
Last updated: Apr 24, 2026, 9:05 AM CET
Market Cap775.22M +20.9%
Revenue (ttm)592.01M -2.0%
Net Income-20.44M
EPS-0.00
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.0780
Previous Close0.0790
Day's Range0.0780 - 0.0780
52-Week Range0.0720 - 0.1130
Betan/a
RSI50.60
Earnings DateMay 12, 2026

About FRA:LSI

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines.... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 1,920
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol LSI

Financial Performance

In 2025, FRA:LSI's revenue was 5.41 billion, a decrease of -2.04% compared to the previous year's 5.52 billion. Losses were -186.81 million, 47.6% more than in 2024.

Financial numbers in HKD Financial Statements

News

Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline

CK Life Sciences, a unit of Li Ka-shing-backed CK Group, plans to bring its cancer vaccine candidates to mainland China through a “fast track” channel as Beijing moves to accelerate early-stage drug d...

25 days ago - South China Morning Post

CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs

CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech...

7 months ago - South China Morning Post

TransCode Acquires Polynoma From CK Life Sciences

(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candi...

7 months ago - Nasdaq

CK Life’s new CEO counts on Big Pharma experience to boost new drug success, earnings

Lance Yuen spent two decades at Bristol-Myers Squibb and Bayer in the region before becoming the CEO at CK Life Sciences last month.

1 year ago - South China Morning Post